IP Library Granted Patent US 12691234
Granted Patent B2
US 12691234 · App. 17/779,709 · Granted Jul 28, 2026

Methods employing gaseous nitric oxide for inhibiting tumor growth

Inventors: Hila Confino (Rehovot, IL); Steven A. Lisi (Garden City, NY); Rinat Kalaora (Rehovot, IL); Amir Avniel (Rehovot, IL)
Assignee: Beyond Air, Inc.
A61M13/003A61K9/0019A61K33/00A61K39/0011A61K40/24A61M39/223A61P35/00A61M2202/0275A61M2205/3334A61M2205/3344A61M2205/7536
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12691234
App. No.
17/779,709
Granted
Jul 28, 2026
Kind
B2
Abstract

Methods of inhibiting growth of cells or tissue of a primary and/or secondary tumor, and/or of stimulating an immunological response to the tumor, in a subject in need thereof, and systems for performing same, are provided. The methods employ local administration of a gas, such as gaseous nitric oxide, typically at a high dose. Immune cells obtained upon treating a tumor with gaseous nitric oxide, either in vivo or ex vivo, and methods employing same are also provided.

Claims (17)

1 . A method of inhibiting growth of cells or tissue of a primary and/or secondary tumor in a subject in need thereof, the method comprising locally administering to the tumor gaseous nitric oxide (gNO) at a dose of from about 1,000 ppm to about 1,000,000 ppm for a time period of from about 1 second to about 60 minutes at a volumetric flow of from about 0.00001 LPM to about 1 LPM, wherein locally administering said gNO is by intratumoral injection.

2 . The method according to claim 1 , wherein the gNO is administered at a dose of from about 20,000 ppm to about 200,000 ppm or from about 20,000 ppm to about 50,000 ppm.

3 . The method according to claim 1 , wherein the gNO is administered for a time period that ranges from about 30 seconds to about 10 minutes.

4 . The method according to claim 1 , wherein the gNO is administered at a volumetric flow of from about 0.001 LPM to about 0.5 LPM.

5 . The method according to claim 1 , wherein the gNO is administered at two or more administration sites in the tumor.

6 . The method according to claim 5 , wherein the distance between the two or more administration sites is, independently, from about 2.5 mm to about 1 cm, or from about 0.25 cm to about 0.5 cm.

7 . The method according to claim 1 , wherein the gNO is administered at a dose of from about 0.1 mg to about 300 mg, per cm 3 tumor.

8 . The method according to claim 1 , wherein gNO is administered at a dose of from about 0.01 mg to about 100 mg, or from 0.1 mg to about 10 mg, per a tumor of 20 mm 3 or less.

9 . The method according claim 1 , further comprising scavenging excess gNO from the administration site.

10 . The method according to claim 1 , wherein locally administering said gNO is pulsed from about 2 to about 20 times.

11 . The method according to claim 1 , wherein locally administering said gNO to the subject is performed at least once.

12 . The method according to claim 1 , wherein locally administering said gNO to the subject is performed at least twice, and wherein a time interval between said two administrations is at least one week.

13 . The method according to claim 1 , further comprising co-administering to the subject an anti-cancer therapy.

14 . The method according to claim 1 , being for inhibiting growth and/or killing cells of a primary tumor.

15 . The method according to claim 1 , being for preventing occurrence, inhibiting growth and/or killing cells of a secondary tumor.

16 . The method according to claim 1 , wherein said secondary tumor comprises metastasizing tumor and/or a recurrent tumor.

17 . The method according to claim 1 , being for stimulating in the subject an immunological response to the tumor, thereby inhibiting growth of a primary tumor and/or a secondary tumor.